Avaliação dos efeitos no uso de antirretrovirais da classe dos inibidores de protease no metabolismo de lipídios em pacientes idosos com HIV

Abstract

The increase in life expectancy associated with advances in medicine is related to the increase in the number of patients with chronic and infectious diseases such as HIV/AIDS. Currently, HIV treatment is carried out with the use of antiretrovirals (ARVs) such as protease inhibitors (PI) which have as an adverse effect the development of dyslipidemia on the part of patients who use them. Among the various drugs used to treat dyslipidemia, atorvastatin and gemfibrozil are the most used by this population. Thus, in order to evaluate the effects of the use of class IP ARVs on lipid metabolism in the elderly (over 50 years old), a cross-sectional retrospective study was carried out for the period from 2017 to 2022, through the analysis of data from these patients being treated with the above-mentioned drugs. It was possible to verify that most of the patients had diagnosis time between 10 and 15 years and arterial hypertension was the most prevalent comorbidity. Darunavir (60%) is the PI used by most patients, along with atorvastatin as a dyslipidemic agent. Regarding the lipid profile, men had higher triglyceride values than women and cholesterol values were similar for both sexes. Finally, when assessing the Castelli I and II indexes, it is clear that the values remained within normal limits. Through this study, it was possible to verify that the patients had a good adherence to the treatment since they did not manifest important alterations in the evaluated diseases and, therefore, they present a control in the disease and a lower risk of developing cardiovascular problems, which, possibly, leads these patients to a better quality of life.